Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NCE 401 (Primary) ; Pembrolizumab (Primary)
  • Indications Biliary cancer; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors TiumBio

    • Most Recent Events

    • 04 Oct 2024 According to TiumBio media release, the first patient has been dosed in Phase 2 clinical trial, first dose was administered to an HNSCC patient. as well as biliary tract cancer patients. It will be later expanded to colorectal cancer patients.
    • 11 Mar 2024 According to TiumBio media release, the phase 2a study will enroll up to 116 evaluable participants across three cohorts (up to 40 participants for BTC, up to 36 participants for HNSCC, and up to 40 participants for CRC, respectively)
    • 11 Mar 2024 According to TiumBio media release, for the Phase 2a trial, the company has selected indications in biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top